Coulter licenses cancer compounds from Kyowa

Kyowa Hakko Kogyo (Tokyo, Japan) granted CLTR exclusive worldwide rights to its Duocarmycin B2 and KW-2189 chemotherapeutics. CLTR said it will use its tumor activated prodrug (TAP) and tumor specific...